难治性癌症基于分子谱的靶向治疗：开放标签II期篮式试验（Long March Pathway）Table_2

数据集获取（Figshare）

• 源站标题：Table_2_Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway).xlsx
• DOI：10.3389/fonc.2023.860711.s003
• 发布日期：2023-02-23
• 文件数：1 个
• 文件总体积：32.87 KB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/Table_2_Targeted_therapy_for_intractable_cancer_on_the_basis_of_molecular_profiles_An_open-label_phase_II_basket_trial_Long_March_Pathway_xlsx/22145912

命令行下载

curl -L -o "Table_2_Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway).xlsx" "https://ndownloader.figshare.com/files/39371258"

文件清单

• Table_2_Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway).xlsx（32.87 KB）

文件总体积 32.87 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

PurposeWe evaluated he effects of molecular guided-targeted therapy for intractable cancer. Also, the epidemiology of druggable gene alterations in Chinese population was investigated.
Materials and methodsThe Long March Pathway (ClinicalTrials.gov identifier: NCT03239015) is a non-randomized, open-label, phase II trial consisting of several basket studies examining the molecular profiles of intractable cancers in the Chinese population. The trial aimed to 1) evaluate the efficacy of targeted therapy for intractable cancer and 2) identify the molecular epidemiology of the tier II gene alterations among Chinese pan-cancer patients.
ResultsIn the first stage, molecular profiles of 520 intractable pan-cancer patients were identified, and 115 patients were identified to have tier II gene alterations. Then, 27 of these 115 patients received targeted therapy based on molecular profiles. The overall response rate (ORR) was 29.6% (8/27), and the disease control rate (DCR) was 44.4% (12/27). The median duration of response (DOR) was 4.80 months (95% CI, 3.33−27.2), and median progression-free survival (PFS) was 4.67 months (95% CI, 2.33−9.50). In the second stage, molecular epidemiology of 17,841 Chinese pan-cancer patients demonstrated that the frequency of tier II gene alterations across cancer types is 17.7%. Bladder cancer had the most tier-II alterations (26.1%), followed by breast cancer (22.4%), and non-small cell lung cancer (NSCLC; 20.2%).
ConclusionThe Long March Pathway trial demonstrated a significant clinical benefit for intractable cancer from molecular-guided targeted therapy in the Chinese population. The frequency of tier II gene alterations across cancer types supports the feasibility of molecular-guided targeted therapy under basket trials.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fonc.2023.860711.s003（source: https://frontiersin.figshare.com/articles/dataset/Table_2_Targeted_therapy_for_intractable_cancer_on_the_basis_of_molecular_profiles_An_open-label_phase_II_basket_trial_Long_March_Pathway_xlsx/22145912）。